ZLAB Zai Lab Ltd: רווח למניה בשנים עשר החודשים האחרונים

Zai Lab Limited scales revenue by licensing foreign drugs in China, thereby minimizing R&D costs. The YoY (ttm) EPS percentage growth history visualizes the market valuation through earnings per share dynamics, where the value of 8.20 expresses the metric level. Efficient cross-border logistics reduce shortage risks, while the integration of oncology drugs into insurance systems accelerates the holding's expansion.

Year-over-year EPS growth (TTM) measures the rate of change in net income per share over a rolling year, neutralizing seasonal distortions and demonstrating real efficiency in capital generation. By analyzing the historical annual dynamics of EPS TTM, an investor can see how the strategy of licensing Western drugs and the development of IT distribution at Zai Lab Limited (ZLAB) convert sales into margins without R&D costs, confirming the sustainability of the business value.